Abstract:ObjectiveTo explore aescin‘ s inhibition of in vitro proliferatim in L1210 murine acute lymphoid leukemia cells and its in vivo antileukemic effects.Methods MTT assay was used to determine the anti-proliferative effect in vitro;Leukemia transplant models were used to test the antileukemic effect.Mice inoculated with L1210 cells were treated with ten daily doses of aescin or/and each other day of DOX,and were observed for survival.Antileukemic effects were assessed by calculating the extension of lifespan.Results Aescin (20一60 p.g/mL) was found to be able to inhibit the proliferation of L1210 cells. The effects were in a dose-and time-dependent manner.The IC50, value of aescin in L1210 cells after 72h was (24.86±2.23) ug/mL.In vivo study showed that after treating the L1210 cells bearing mice with higher,middle,and low dosage(4:5,3.5,and 2.5 mg/kg) of aescin for ten consecutive days,The extension of lifespan were 25. 8%(P<0.O1),32.3%(P<0.0l),and 12.9%,respectively.Moreover, the extension of lifespan was 45.2%when mice were treated with a low dose of aescin in combination with DOX(2mg/kg),which was significantly increased compared with 29.0% when treated with singleDOX (P<0.01).
Conclusion The data presented here indicate that aescm is a poent natural inhibitor of proliferation in L1210 lymphoid leukemia cells and aesctn has the potential to be a promising candidate for cancer treatment.